Data repository FMRI ROS paper.zip

Theranostic systems that integrate therapeutic delivery with diagnostic imaging hold strong potential in biomedical applications. Nanocarriers with imaging and controlled release functions enable real-time tracking and localization of therapeutics, while hydrogels with diagnostic capabilities support applications such as sustained drug release, cell encapsulation, and cell tracking. Fluorine-19 magnetic resonance imaging (¹⁹F MRI) is a promising non-invasive complement to conventional proton MRI, though its clinical translation remains limited by the lack of optimal tracer systems. Herein, we report the development of BAB-type triblock copolymers comprising a hydrophilic poly(2-ethyl-2-oxazoline) (PEtOx) A block and a thermoresponsive poly[N-(2,2-difluoroethyl)acrylamide] (PDFEA) B block, statistically copolymerized with a ROS-responsive monomer bearing phenylboronic ester groups. These polymers self-assemble into nanoparticles at low concentrations and form thermogelling hydrogels at higher concentrations, allowing for formulation-dependent versatility. The ROS-sensitive component enables disassembly at pathophysiologically relevant ROS levels (~0.4–2 mM), facilitating targeted therapeutic release in oxidative environments such as tumors. The polymers form physically crosslinked nanogels (hydrodynamic radius ≈160–760 nm) at 37 °C, which undergo ROS-triggered disassembly. Selected formulations demonstrated excellent ¹⁹F MRI relaxation properties suitable for in vivo imaging. Cytocompatibility was confirmed in vitro using human foreskin fibroblasts. Overall, the developed polymers offer a versatile platform for biomedical applications—ranging from thermogelling injectable hydrogels for drug delivery or cell encapsulation, to nanocarriers for ROS-triggered therapeutic release—all while enabling non-invasive monitoring via ¹⁹F MRI.